Citation

Gale RP, Butturini A. Exp. Hematol. 1990; 18(8): 958-964.

Affiliation

Department of Medicine, UCLA School of Medicine 90024-1678.

Copyright

(Copyright © 1990, Elsevier Publishing)

DOI

unavailable

PMID

2201559

Abstract

Molecularly cloned hematopoietic growth factors are likely to be useful in treating persons with bone marrow failure resulting from radiation exposure. Some effects, such as increased granulocytes or platelets, are of clear therapeutic benefit. Other effects, such as a direct action on survival of hematopoietic stem cells and improved granulocyte function, may also increase survival. Many important areas remain to be studied, including which molecularly cloned hematopoietic growth factor(s) to use, optimal dose and timing, and others. Some of these issues can be studied in clinical trials; others require in vitro or animal models. Despite the limited data currently available, it is clear that the availability of molecularly cloned hematopoietic growth factors heralds a new era in treating radiation and nuclear accidents.

Language: en